A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS

Summary

This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.

Eligibility

Age range

18–64 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  E coli vaccine 1 Dose A

  Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval

• Drug
  E coli vaccine 1 Dose B

  Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval

• Drug
  E coli vaccine 2

  Candidate E coli vaccine 2, administered according to a 0, 6-month interval

• Drug
  E coli vaccine 3

  Candidate E coli vaccine 3, administered according to a 0, 6-month interval

• Drug
  E coli Vaccine 4 Dose A

  Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval

• Drug
  E coli Vaccine 4 Dose B

  Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval

Locations (11)